Results 21 to 30 of about 62,277 (245)

Iranian psychiatrists’ attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey

open access: yesBMC Psychiatry, 2022
Background Clozapine has the greatest efficacy for treatment-resistant schizophrenia (TRS), even though its underutilization is not uncommon across different countries.
Leeba Rezaie   +4 more
doaj   +1 more source

Locomotor hyperactivity in 14-3-3Zeta KO mice is associated with dopamine transporter dysfunction [PDF]

open access: yes, 2013
Dopamine (DA) neurotransmission requires a complex series of enzymatic reactions that are tightly linked to catecholamine exocytosis and receptor interactions on pre- and postsynaptic neurons.
A Abi-Dargham   +53 more
core   +2 more sources

Infections associated with clozapine: a pharmacovigilance study using VigiBase®

open access: yesFrontiers in Pharmacology, 2023
Introduction: Clozapine is primarily reserved for treatment-resistant schizophrenia due to safety concerns associated with its use. Infections have been reported with clozapine, which may lead to elevated serum levels of the drug.
Basile Chrétien   +11 more
doaj   +1 more source

Factors associated with costs of hospitalization of severely mentally Ill patients [PDF]

open access: yes, 2016
Background: Efforts to contain costs associated with general medical care include particular efforts for psychiatric disorders. Hospitalization represents the largest component of costs for psychiatric care and there is growing interest in balancing ...
Baldessarini, RossJ   +4 more
core   +1 more source

Global Connectivity and Function of Descending Spinal Input Revealed by 3D Microscopy and Retrograde Transduction [PDF]

open access: yes, 2018
The brain communicates with the spinal cord through numerous axon tracts that arise from discrete nuclei, transmit distinct functions, and often collateralize to facilitate the coordination of descending commands.
Blackmore, Murray G.   +4 more
core   +2 more sources

Reasons for admission to a general medical hospital for patients taking clozapine

open access: yesTherapeutic Advances in Psychopharmacology, 2022
Background: Clozapine is associated with a diverse range of side effects. In addition, patients prescribed clozapine commonly suffer with medical comorbidities.
Siobhan Gee   +4 more
doaj   +1 more source

Clozapine for treatment-resistant schizophrenia with epilepsy: A case report. [PDF]

open access: yesPCN Rep
Clozapine (CLOZ) is often avoided in treatment‐resistant schizophrenia with comorbid epilepsy due to seizure risks. We report a successful case managed through a cautious CLOZ titration guided by multimodal monitoring, including clinical scales and blood tests such as C‐reactive protein (CRP), CLOZ levels, and anti‐seizure medication (ASM) levels ...
Horinouchi T   +5 more
europepmc   +2 more sources

Clinical relevance and treatment possibilities of bipolar rapid cycling [PDF]

open access: yes, 2002
Bipolar rapid cycling (RC) is defined as 4 or more affective episodes within 1 year. It has been postulated that RC is related to a poor response to lithium, to the same extent as mixed episodes or other atypical symptoms of the illness.
Amann, B.   +3 more
core   +1 more source

Patterns of clozapine use, misuse and disuse in a mental health area in southern Spain

open access: yesEuropean Psychiatry, 2022
Introduction Evidence supports clozapine as the best treatment in terms of efficacy, effectiveness and well-being, and as the gold standard in treatment-resistant psychotic disorders. Clozapine remains still underused, suffering initiation delays from 1.
L.I. Muñoz-Manchado   +7 more
doaj   +1 more source

Effects of haloperidol and atypical neuroleptics on psychomotor performance and driving ability in schizophrenic patients - Results from an experimental study [PDF]

open access: yes, 2003
The influence of antipsychotic treatment on the neuropsychological and psychomotor performance of schizophrenic patients is still a subject of investigation.
Kagerer, S.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy